BBK Worldwide has raised $3 million to finance an expansion of its suite of eClinical software.
The University of California has been a rich source of innovative new medicines. It's outlicensed the IP behind such standout biotechs as Aragon and Seragon--twin biotech sisters bought out by pharma giants--as well as Kite Pharma, a recent IPO success focused on CAR-T. And now it wants a bigger piece of the action.
Dow Jones writer Brian Gormley set out to find out the answer to that question, reviewing the venture data for biotech and med tech in Dow Jones' VentureSource database.
Scholar Rock has banked a $20 million A round, bringing in some new backers to fuel the early stage of development for its immune system-modulating drug platform technology.
Xenon Pharmaceuticals has gone 8 long years since its last equity raise, relying on a slate of partnerships with some of the biggest names in the business to fund its work. And now it's set out to test the fall biotech IPO market with a $52 million offering designed to take the company down another stage of its journey through the clinic.
Venture capital stalwart OrbiMed Advisors has closed a $325 million new fund, cash earmarked for biotech investments in Asia.
Proving once again that Christoph Westphal has some of the best connections in the biotech industry, the controversial entrepreneur has pieced together a $40 million financing round for his new startup Flex Pharma. And he did it by tapping a long lineup of investors, including some high profile individuals in the Boston area.
The tech-driven reimagining of well-established clinical research and healthcare practices is continuing apace, with Propeller Health raising $14.5 million to develop its GPS-enabled inhaler. Users attach a small device to the end of their inhaler which tracks when and where a dose was administered.
Yesterday, Seattle-based VentiRx Pharmaceuticals put out the word that it had raised a new round of cash to back an ongoing mid-stage study of motolimod (VTX-2337), its TLR8 cancer vaccine, adding that the biotech had won fast-track status for the program. And today the company is following up with the news that it's partnering with the Ludwig Cancer Research and the Cancer Research Institute on a new immuno-oncology combo development effort with AstraZeneca's hot checkpoint inhibitor MEDI-4736.
Biotech investing is sizzling right now, and despite all the attention that the Boston hub gets, the Bay Area is still number one.